Several meta-analyses have shown that primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) can reduce the risk of FN by up to 50% in patients with solid cancers and malignant lymphomas [5,6,7,8]. This evidence concerns the gene CSF3 and lymphoma.